The Scottish Medicines Consortium (SMC) has approved Zinbryta (daclizumab) as a treatment for relapsing remitting multiple sclerosis on the NHS in Scotland.
Ocrelizumab (Ocrevus) has become the first medicine to be licensed for primary progressive MS by the FDA (Food and Drug Administration), the American drug regulators. The FDA has also licensed ocrelizumab as a treatment for relapsing remitting MS.
NICE (National Institute for Health and Care Excellence) has approved Zinbryta (daclizumab) as a treatment for relapsing remitting multiple sclerosis on the NHS in England and Wales.
Researchers have discovered a protein that encourages the regrowth of myelin and may lead to new types of treatment for MS in the future
Two new reports published this week have highlighted the problems facing people trying to access neurological services in the UK
Canadian researchers have presented preliminary results from a clinical study which suggest that surgical treatment to unblock veins draining the brain and spinal cord is not effective in treating MS.
Two recently published studies have reported data on levels of disability in people with MS five years after receiving stem cell transplants.
The full results of the latest ocrelizumab trials have been published in the New England Journal of Medicine.
Babies born with low levels of vitamin D may be more likely to develop multiple sclerosis in later life, according to newly-published research.